Head-to-Head Biologics Trial Shows No Difference between Abatacept and Adalimumab

Summary

Outcomes from the Abatacept Versus Adalimumab Head-to-Head [AMPLE; NCT00929864] trial demonstrated comparable efficacy between subcutaneous abatacept and adalimumab on background methotrexate. This article discusses key efficacy and safety results from the trial.

  • Rheumatoid Arthritis
  • Rheumatology Clinical Trials
View Full Text